Fleury (FLRY3) entered into a Binding Memorandum of Understanding on Tuesday, November 10, 2026, with Atlântica Hospitais e Participações, indirectly controlled by Bradsaúde, part of the Bradesco group. The agreement provides for Atlântica's investment in FleuryOnco, a company created to develop the outpatient oncology business through oncology clinics. The investment planned for this initial phase is R$ 72 mi through 2027.
After the transaction closes, FleuryOnco will be 50.1% owned by Fleury and 49.9% by Atlântica. Fleury will retain control and the medical, operational and commercial management. The R$ 72 mi in contributions will be made by both companies in proportion to their ownership stakes.
The business will have seven clinics in São Paulo and Rio de Janeiro, with openings scheduled between 2026 and 2027. The Fleury Oncologia brand will operate in São Paulo, with two clinics. The Onco One brand will be national, endorsed by Grupo Fleury, and will start with three clinics in São Paulo and two in Rio de Janeiro. The brands will be contributed or licensed by Fleury to FleuryOnco.
According to the company, Fleury is already a reference in oncology testing, such as clinical analyses, pathology, imaging and genomics. The partnership strengthens its expansion into outpatient oncology clinics, with services such as chemotherapy, and adds to the greenfield (new projects), brownfield (expansion of existing units) and acquisition strategies, which will continue to be pursued.
Completion of the transaction depends on customary conditions, including CADE approval and the signing of definitive documents, including an Investment Agreement and a Shareholders' Agreement. The company stated that it will keep the market updated on the matter.
